PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Anticoagulants: An overview • Coagulation of blood • Mechanism of action (MOA) of anticoagulants PART 06: Reimbursement scenario • US healthcare reform • Reimbursement for prothrombin time/international normalized ratio (PT/INR) tests PART 07: Anticoagulant reversal agents PART 08: Approved anticoagulants in US PART 09: Anticoagulants pipeline portfolio • Rivaroxaban • Tecarfarin • Betrixaban (LY517717) • ISIS-FXI antisense • LMW Heparin MMX • URG101 • Heparin • FXI antibody • FXI inhibitor • Heparin plus DNAse • Heparin plus other inhaled drug PART 10: Market landscape • Global anticoagulants market • Anticoagulants market in US • Five forces analysis PART 11: Market segmentation by ROA • Oral anticoagulants • Injectable anticoagulants PART 12: Market segmentation by drug class • Factor Xa inhibitors • Direct thrombin inhibitors • Heparin • Vitamin K antagonists PART 13: Market segmentation by application • DVT • PE • Acute coronary syndrome • AF • Hemodialysis • Coronary angioplasty • Surgeries PART 14: Market drivers • Growing prevalence of coagulation disorders • Increase in number of surgical procedures • Increased acceptance of NOACs PART 15: Impact of drivers PART 16: Market challenges • Extensive use of generic products • Side-effects associated with drugs • High cost of NOACs • Unmet needs for anticoagulant reversal agents PART 17: Impact of drivers and challenges PART 18: Market trends • Expected exploitation of new therapeutic use • Patient assistance programs • Declining shares of heparin market PART 19: Vendor landscape • Competitive scenario • Market analysis 2015 • Key vendors of anticoagulants market in US • Johnson & Johnson • Bristol-Myers Squibb • Boehringer Ingelheim • Sanofi • Upcoming vendors in anticoagulants market in US • Daiichi Sankyo • Other prominent vendors PART 20: Appendix • List of abbreviations PART 21: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Timeline for development of anticoagulants Exhibit 03: Process of blood coagulation Exhibit 04: Mechanism of blood coagulation Exhibit 05: Comparison of US healthcare system before and after reforms Exhibit 06: Major anticoagulant reversal agents commonly used in market Exhibit 07: Reversal agents approved by FDA for new oral anticoagulants Exhibit 08: Pipeline portfolio: Anticoagulant reversal agents Exhibit 09: Approved anticoagulants in US Exhibit 10: Pipeline portfolio: Anticoagulant drugs Exhibit 11: Global anticoagulants market 2015-2020 ($ billions) Exhibit 12: Percentage share of US anticoagulants market in global market Exhibit 13: Anticoagulants market in US 2015-2020 ($ billions) Exhibit 14: Five forces analysis Exhibit 15: Segmentation of anticoagulants market in US based on ROA Exhibit 16: Market segmentation of anticoagulants market in US based on ROA 2015 Exhibit 17: Comparison of US anticoagulants market with global anticoagulants market 2015 Exhibit 18: Percentage of population treated by NOACs based on disease type in US 2015 Exhibit 19: Factors determining use of NOACs (based on their importance) Exhibit 20: Percentage of individuals with AF treated by anticoagulants in US 2015 Exhibit 21: Percentage of individuals with DVT/PE treated by anticoagulants in US 2015 Exhibit 22: Classes of oral anticoagulants based on revenue 2015 Exhibit 23: Oral anticoagulants market in US 2015-2020 ($ billions) Exhibit 24: Classes of injectable anticoagulants based on revenue 2015 Exhibit 25: Injectable anticoagulants market in the US 2015-2020 ($ billions) Exhibit 26: Anticoagulants market in US by ROA 2015-2020 Exhibit 27: Anticoagulants market in US: YoY growth and revenue based on ROA 2015-2020 Exhibit 28: Segmentation of anticoagulants market in US based on drug class Exhibit 29: Segmentation of anticoagulants market in US based on drug class 2015 Exhibit 30: Anticoagulants market in US in global anticoagulant drugs market 2015 Exhibit 31: Segmentation of factor Xa inhibitors in US 2015 Exhibit 32: Approval of factor Xa inhibitor drugs in US Exhibit 33: Factor Xa inhibitor drugs market in US 2015-2020 ($ billions) Exhibit 34: Some direct thrombin inhibitor drugs approved in US Exhibit 35: Direct thrombin inhibitors market segmentation by ROA 2015 Exhibit 36: Direct thrombin inhibitor drugs market in US 2015-2020 ($ billions) Exhibit 37: Segmentation of global heparin market by product type 2015 Exhibit 38: Global heparin market 2015-2020 ($ billions) Exhibit 39: Heparin market in US 2015-2020 ($ billions) Exhibit 40: Vitamin K antagonists market in US 2015-2020 ($ millions) Exhibit 41: Anticoagulants market in US by drug class 2015-2020 Exhibit 42: Anticoagulants market in US: YoY growth and revenue based on drug class 2015-2020 Exhibit 43: Expected growth of older population in US 2010-2050 Exhibit 44: Impact of drivers Exhibit 45: Impact of drivers and challenges Exhibit 46: Share of the major anticoagulant drugs in US 2013-2015 ($ billions) Exhibit 47: Johnson & Johnson: YoY revenue and growth rate of Xarelto in US 2013-2015 ($ millions) Exhibit 48: Johnson & Johnson: Key takeaways Exhibit 49: BMS: YoY revenue and growth rate of Eliquis in US 2013-2015 ($ millions) Exhibit 50: BMS: Key takeaways Exhibit 51: Boehringer Ingelheim: YoY revenue and growth rate of Pradaxa (global) 2013-2015 ($ billions) Exhibit 52: Boehringer Ingelheim: Key takeaways Exhibit 53: Sanofi: YoY revenue and growth rate of Lovenox in US 2013-2015 ($ millions) Exhibit 54: Geographical segmentation of Lovenox 2015 Exhibit 55: Sanofi: Key takeaways Exhibit 56: Key takeaways

Johnson & Johnson, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Armatheon Inc., Aspen, AstraZeneca, Bayer, Cellceutix, Cosmo Pharmaceuticals SA, CSL Behring, Eisai, GSK, Marathon Pharmaceuticals LLC, Ockham Biotech, Perosphere, Portola Pharmaceuticals, Sagent Pharmaceuticals Inc., The Medicines Company, Urigen Pharmaceuticals Inc., Valeant Pharmaceuticals.